Neurobiological Interactions Between Stress and the Endocannabinoid System

Neuropsychopharmacology

Volumn 41, Issue 1, 2016, Pages 80-102

  Morena, Maria ^a,b   Patel, Sachin ^c   Bains, Jaideep S ^a,b   Hill, Matthew N ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYL GLYCEROL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; GLYCEROL DERIVATIVE; UNCLASSIFIED DRUG; ACYLGLYCEROL; AMIDE; ARACHIDONIC ACID DERIVATIVE; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AFFECTING AGENT; GLYCERYL 2-ARACHIDONATE;

ACUTE STRESS; ANXIETY; BRAIN LEVEL; BRAIN REGION; CHRONIC STRESS; DOWN REGULATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MEMORY; NERVE CELL PLASTICITY; NEUROBIOLOGY; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; REVIEW; REWARD; ROLE CHANGE; STRESS; ANIMAL; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MENTAL STRESS; METABOLISM; PATHOLOGY; PSYCHOLOGY;

ANIMALS; ARACHIDONIC ACIDS; CANNABINOID RECEPTOR MODULATORS; ENDOCANNABINOIDS; GLYCERIDES; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; POLYUNSATURATED ALKAMIDES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; STRESS, PSYCHOLOGICAL;

EID: 84949543999     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.166     Document Type: Review

References (275)

1. Agrawal A, Nelson EC, Littlefield AK, Bucholz KK, Degenhardt L, Henders AK et al (2012). Cannabinoid receptor genotype moderation of the effects of childhood physical abuse on anhedonia and depression. Arch Gen Psychiatry 69: 732-740.
2. Aguado T, Monory K, Palazuelos J, Stella N, Cravatt B, Lutz B et al (2005). The endocannabinoid system drives neural progenitor proliferation. FASEB J 19: 1704-1706.
3. Ahn K, McKinney MK, Cravatt BF (2008). Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 108: 1687-1707.
4. Akirav I, Kozenicky M, Tal D, Sandi C, Venero C, Richter-Levin G (2004). A facilitative role for corticosterone in the acquisition of a spatial task under moderate stress. Learn Mem 11: 188-195.
5. Aliczki M, Balogh Z, Tulogdi A, Haller J (2012). The temporal dynamics of the effects of monoacylglycerol lipase blockade on locomotion, anxiety, and body temperature. Behav Pharmacol 23: 348-357.
6. Aliczki M, Zelena D, Mikics E, Varga ZK, Pinter O, Bakos NV et al (2013). Monoacylglycerol lipase inhibition-induced changes in plasma corticosterone levels, anxiety and locomotor activity in male CD1 mice. Horm Behav 63: 752-758.
7. Atkinson HC, Leggett JD, Wood SA, Castrique ES, Kershaw YM, Lightman SL (2010). Regulation of the hypothalamic-pituitary-adrenal axis circadian rhythm by endocannabinoids is sexually diergic. Endocrinology 151: 3720-3727.
8. Atsak P, Hauer D, Campolongo P, Schelling G, Fornari RV, Roozendaal B (2014). Endocannabinoid signaling within the basolateral amygdala integrates multiple stress hormone effects on memory consolidation. Neuropsychopharmacology 40: 1485-1494.
9. Atsak P, Hauer D, Campolongo P, Schelling G, McGaugh JL, Roozendaal B (2012a). Glucocorticoids interact with the hippocampal endocannabinoid system in impairing retrieval of contextual fear memory. Proc Natl Acad Sci USA 109: 3504-3509.
10. Atsak P, Roozendaal B, Campolongo P (2012b). Role of the endocannabinoid system in regulating glucocorticoid effects on memory for emotional experiences. Neuroscience 204: 104-116.
11. Atwood BK, Mackie K (2010). CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 160: 467-479.
12. Atwood BK, Straiker A, Mackie K (2012). CB(2): therapeutic target-in-waiting. Prog Neuropsychopharmacol Biol Psychiatry 38: 16-20.
13. Azad SC, Eder M, Marsicano G, Lutz B, Zieglgansberger W, Rammes G (2003). Activation of the cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse. Learn Mem 10: 116-128.
14. Azad SC, Kurz J, Marsicano G, Lutz B, Zieglgansberger W, Rammes G (2008). Activation of CB1 specifically located on GABAergic interneurons inhibits LTD in the lateral amygdala. Learn Mem 15: 143-152.
15. Bains JS, Cusulin JI, Inoue VV (2015). Stress-related synaptic plasticity in the hypothalamus. Nat Rev Neurosci 16: 377-388.
16. Bedse G, Colangeli R, Lavecchia AM, Romano A, Altieri F, Cifani C et al (2014). Role of the basolateral amygdala in mediating the effects of the fatty acid amide hydrolase inhibitor URB597 on HPA axis response to stress. Eur Neuropsychopharmacol 24: 1511-1523.
17. Bellocchio L, Soria-Gomez E, Quarta C, Metna-Laurent M, Cardinal P, Binder E et al (2013). Activation of the sympathetic nervous system mediates hypophagic and anxiety-like effects of CB(1) receptor blockade. Proc Natl Acad Sci USA 110: 4786-4791.
18. Bentz D, Michael T, Wilhelm FH, Hartmann FR, Kunz S, von Rohr IR et al (2013). Influence of stress on fear memory processes in an aversive differential conditioning paradigm in humans. Psychoneuroendocrinology 38: 1186-1197.
19. Bergamaschi MM, Queiroz RH, Chagas MH, Linares IM, Arrais KC, de Oliveira DC et al (2014). Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: a preliminary report. Hum Psychopharmacol 29: 94-99.
20. Bishop SJ (2008). Neural mechanisms underlying selective attention to threat. Ann NY Acad Sci 1129: 141-152.
21. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A et al (2003). Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 163: 463-468.
22. Bitencourt RM, Pamplona FA, Takahashi RN (2008). Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats. Eur Neuropsychopharmacol 18: 849-859.
23. Bitencourt RM, Pamplona FA, Takahashi RN (2014). Corticosteroid-endocannabinoid loop supports decrease of fear-conditioned response in rats. Eur Neuropsychopharmacol 24: 1091-1102.
24. Blankman JL, Simon GM, Cravatt BF (2007). A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 14: 1347-1356.
25. Bluett RJ, Gamble-George JC, Hermanson DJ, Hartley ND, Marnett LJ, Patel S (2014). Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation. Transl Psychiatry 4: e408.
26. Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, Duranti A et al (2007). Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 62: 1103-1110.
27. Bouchez G, Millan MJ, Rivet JM, Billiras R, Boulanger R, Gobert A (2012). Quantification of extracellular levels of corticosterone in the basolateral amygdaloid complex of freely-moving rats: a dialysis study of circadian variation and stress-induced modulation. Brain Res 1452: 47-60.
28. Bowles NP, Hill MN, Bhagat SM, Karatsoreos IN, Hillard CJ, McEwen BS (2012). Chronic, noninvasive glucocorticoid administration suppresses limbic endocannabinoid signaling in mice. Neuroscience 204: 83-89.
29. Bowles NP, Karatsoreos IN, Li X, Vemuri VK, Wood JA, Li Z et al (2015). A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome. Proc Natl Acad Sci USA 112: 285-290.
30. Bucherelli C, Baldi E, Mariottini C, Passani MB, Blandina P (2006). Aversive memory reactivation engages in the amygdala only some neurotransmitters involved in consolidation. Learn Mem 13: 426-430.
31. Busquets-Garcia A, Puighermanal E, Pastor A, de la Torre R, Maldonado R, Ozaita A (2011). Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol Psychiatry 70: 479-486.
32. Calabrese F, Molteni R, Racagni G, Riva MA (2009). Neuronal plasticity: a link between stress and mood disorders. Psychoneuroendocrinology 34(Suppl 1): S208-S216.
33. Campolongo P, Ratano P, Manduca A, Scattoni ML, Palmery M, Trezza V et al (2012). The endocannabinoid transport inhibitor AM404 differentially modulates recognition memory in rats depending on environmental aversiveness. Front Behav Neurosci 6: 11.
34. Campolongo P, Roozendaal B, Trezza V, Hauer D, Schelling G, McGaugh JL et al (2009). Endocannabinoids in the rat basolateral amygdala enhance memory consolidation and enable glucocorticoid modulation of memory. Proc Natl Acad Sci USA 106: 4888-4893.
35. Campos AC, Ferreira FR, Guimaraes FS, Lemos JI (2010). Facilitation of endocannabinoid effects in the ventral hippocampus modulates anxiety-like behaviors depending on previous stress experience. Neuroscience 167: 238-246.
36. Campos AC, Ortega Z, Palazuelos J, Fogaca MV, Aguiar DC, Diaz-Alonso J et al (2013). The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. Int J Neuropsychopharmacol 16: 1407-1419.
37. Chen K, Neu A, Howard AL, Foldy C, Echegoyen J, Hilgenberg L et al (2007). Prevention of plasticity of endocannabinoid signaling inhibits persistent limbic hyperexcitability caused by developmental seizures. J Neurosci 27: 46-58.
38. Chen K, Ratzliff A, Hilgenberg L, Gulyas A, Freund TF, Smith M et al (2003). Longterm plasticity of endocannabinoid signaling induced by developmental febrile seizures. Neuron 39: 599-611.
39. Chhatwal JP, Davis M, Maguschak KA, Ressler KJ (2005). Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 30: 516-524.
40. Chiang KP, Gerber AL, Sipe JC, Cravatt BF (2004). Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Hum Mol Genet 13: 2113-2119.
41. Chouker A, Kaufmann I, Kreth S, Hauer D, Feuerecker M, Thieme D et al (2010). Motion sickness, stress and the endocannabinoid system. PLoS One 5: e10752.
42. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007). Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370: 1706-1713.
43. Conzelmann A, Reif A, Jacob C, Weyers P, Lesch KP, Lutz B et al (2012). A polymorphism in the gene of the endocannabinoid-degrading enzyme FAAH (FAAH C385A) is associated with emotional-motivational reactivity. Psychopharmacology (Berl) 224: 573-579.
44. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR et al (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98: 9371-9376.
45. Cristino L, Starowicz K, De Petrocellis L, Morishita J, Ueda N, Guglielmotti V et al (2008). Immunohistochemical localization of anabolic and catabolic enzymes for anandamide and other putative endovanilloids in the hippocampus and cerebellar cortex of the mouse brain. Neuroscience 151: 955-968.
46. Dallman MF (2005). Adrenocortical function, feedback, and alphabet soup. Am J Physiol Endocrinol Metab 289: E361-E362.
47. De Chiara V, Errico F, Musella A, Rossi S, Mataluni G, Sacchetti L et al (2010). Voluntary exercise and sucrose consumption enhance cannabinoid CB1 receptor sensitivity in the striatum. Neuropsychopharmacology 35: 374-387.
48. de Kloet ER, Oitzl MS, Joels M (1999). Stress and cognition: are corticosteroids good or bad guys? Trends Neurosci 22: 422-426.
49. de Mattos Viana B, Prais HA, Daker MV (2009). Melancholic features related to rimonabant. Gen Hosp Psychiatry 31: 583-585.
50. de Oliveira Alvares L, de Oliveira LF, Camboim C, Diehl F, Genro BP, Lanziotti VB et al (2005). Amnestic effect of intrahippocampal AM251, a CB1-selective blocker, in the inhibitory avoidance, but not in the open field habituation task, in rats. Neurobiol Learn Mem 83: 119-124.
51. de Oliveira Alvares L, Engelke DS, Diehl F, Scheffer-Teixeira R, Haubrich J, de Freitas Cassini L et al (2010). Stress response recruits the hippocampal endocannabinoid system for the modulation of fear memory. Learn Mem 17: 202-209.
52. de Oliveira Alvares L, Genro BP, Vaz Breda R, Pedroso MF, Da Costa JC, Quillfeldt JA (2006). AM251, a selective antagonist of the CB1 receptor, inhibits the induction of long-term potentiation and induces retrograde amnesia in rats. Brain Res 1075: 60-67.
53. de Quervain DJ, Aerni A, Schelling G, Roozendaal B (2009). Glucocorticoids and the regulation of memory in health and disease. Front Neuroendocrinol 30: 358-370.
54. de Quervain DJ, Roozendaal B, McGaugh JL (1998). Stress and glucocorticoids impair retrieval of long-term spatial memory. Nature 394: 787-790.
55. De Vries TJ, Shaham Y, Homberg JR, Crombag H, Schuurman K, Dieben J et al (2001). A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 7: 1151-1154.
56. DePoy L, Daut R, Brigman JL, MacPherson K, Crowley N, Gunduz-Cinar O et al (2013). Chronic alcohol produces neuroadaptations to prime dorsal striatal learning. Proc Natl Acad Sci USA 110: 14783-14788.
57. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G et al (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949.
58. Di Marzo V, De Petrocellis L (2012). Why do cannabinoid receptors have more than one endogenous ligand?. Philos Trans R Soc Lond B Biol Sci 367: 3216-3228.
59. Di S, Malcher-Lopes R, Halmos KC, Tasker JG (2003). Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J Neurosci 23: 4850-4857.
60. Di S, Malcher-Lopes R, Marcheselli VL, Bazan NG, Tasker JG (2005). Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and gamma-aminobutyric acid inputs to hypothalamic magnocellular neurons. Endocrinology 146: 4292-4301.
61. Dincheva I, Drysdale AT, Hartley CA, Johnson DC, Jing D, King EC et al (2015). FAAH genetic variation enhances fronto-amygdala function in mouse and human. Nat Commun 6: 6395.
62. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL et al (2002). Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99: 10819-10824.
63. Diorio D, Viau V, Meaney MJ (1993). The role of the medial prefrontal cortex (cingulate gyrus) in the regulation of hypothalamic-pituitary-adrenal responses to stress. J Neurosci 13: 3839-3847.
64. Dlugos A, Childs E, Stuhr KL, Hillard CJ, de Wit H (2012). Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans. Neuropsychopharmacology 37: 2416-2427.
65. Dominguez G, Faucher P, Henkous N, Krazem A, Pierard C, Beracochea D (2014). Stress induced a shift from dorsal hippocampus to prefrontal cortex dependent memory retrieval: role of regional corticosterone. Front Behav Neurosci 8: 166.
66. Domschke K, Dannlowski U, Ohrmann P, Lawford B, Bauer J, Kugel H et al (2008). Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression. Eur Neuropsychopharmacol 18: 751-759.
67. Doyon C, Denis RG, Baraboi ED, Samson P, Lalonde J, Deshaies Y et al (2006). Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitaryadrenal axis and neuronal activation in lean and obese Zucker rats. Diabetes 55: 3403-3410.
68. Dubreucq S, Matias I, Cardinal P, Haring M, Lutz B, Marsicano G et al (2012). Genetic dissection of the role of cannabinoid type-1 receptors in the emotional consequences of repeated social stress in mice. Neuropsychopharmacology 37: 1885-1900.
69. Dudok B, Barna L, Ledri M, Szabo SI, Szabadits E, Pinter B et al (2015). Cell-specific STORM super-resolution imaging reveals nanoscale organization of cannabinoid signaling. Nat Neurosci 18: 75-86.
70. Economidou D, Mattioli L, Cifani C, Perfumi M, Massi M, Cuomo V et al (2006). Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol selfadministration and ethanol-seeking behaviour in rats. Psychopharmacology (Berl) 183: 394-403.
71. Evanson NK, Tasker JG, Hill MN, Hillard CJ, Herman JP (2010). Fast feedback inhibition of the HPA axis by glucocorticoids is mediated by endocannabinoid signaling. Endocrinology 151: 4811-4819.
72. Fokos S, Panagis G (2010). Effects of delta9-tetrahydrocannabinol on reward and anxiety in rats exposed to chronic unpredictable stress. J Psychopharmacol 24: 767-777.
73. Foldy C, Neu A, Jones MV, Soltesz I (2006). Presynaptic, activity-dependent modulation of cannabinoid type 1 receptor-mediated inhibition of GABA release. J Neurosci 26: 1465-1469.
74. Friemel CM, Zimmer A, Schneider M (2014). The CB1 receptor as an important mediator of hedonic reward processing. Neuropsychopharmacology 39: 2387-2396.
75. Fu J, Bottegoni G, Sasso O, Bertorelli R, Rocchia W, Masetti M et al (2011). A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nat Neurosci 15: 64-69.
76. Gaetani S, Dipasquale P, Romano A, Righetti L, Cassano T, Piomelli D et al (2009). The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs. Int Rev Neurobiol 85: 57-72.
77. Gamble-George JC, Conger JR, Hartley ND, Gupta P, Sumislawski JJ, Patel S (2013). Dissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice. Psychopharmacology (Berl) 228: 401-409.
78. Ganon-Elazar E, Akirav I (2009). Cannabinoid receptor activation in the basolateral amygdala blocks the effects of stress on the conditioning and extinction of inhibitory avoidance. J Neurosci 29: 11078-11088.
79. Ginsberg AB, Pecoraro NC, Warne JP, Horneman HF, Dallman MF (2010). Rapid alteration of stress-induced hypothalamic-pituitary-adrenal hormone secretion in the rat: a comparison of glucocorticoids and cannabinoids. Stress 13: 248-257.
80. Glangetas C, Girard D, Groc L, Marsicano G, Chaouloff F, Georges F (2013). Stress switches cannabinoid type-1 (CB1) receptor-dependent plasticity from LTD to LTP in the bed nucleus of the stria terminalis. J Neurosci 33: 19657-19663.
81. Goodwin RS, Baumann MH, Gorelick DA, Schwilke E, Schwope DM, Darwin WD et al (2012). CB1-cannabinoid receptor antagonist effects on cortisol in cannabis-dependent men. Am J Drug Alcohol Abuse 38: 114-119.
82. Gorzalka BB, Hill MN, Hillard CJ (2008). Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorders. Neurosci Biobehav Rev 32: 1152-1160.
83. Gray JM, Vecchiarelli HA, Morena M, Lee TT, Hermanson DJ, Kim AB et al (2015). Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety. J Neurosci 35: 3879-3892.
84. Gray M, Bingham B, Viau V (2010). A comparison of two repeated restraint stress paradigms on hypothalamic-pituitary-adrenal axis habituation, gonadal status and central neuropeptide expression in adult male rats. J Neuroendocrinol 22: 92-101.
85. Green B, Kavanagh D, Young R (2003). Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev 22: 453-460.
86. Grissom N, Bhatnagar S (2009). Habituation to repeated stress: get used to it. Neurobiol Learn Mem 92: 215-224.
87. Gulyas AI, Cravatt BF, Bracey MH, Dinh TP, Piomelli D, Boscia F et al (2004). Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci 20: 441-458.
88. Gunduz-Cinar O, Hill MN, McEwen BS, Holmes A (2013a). Amygdala FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol Sci 34: 637-644.
89. Gunduz-Cinar O, MacPherson KP, Cinar R, Gamble-George J, Sugden K, Williams B et al (2013b). Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry 18: 813-823.
90. Haj-Dahmane S, Shen RY (2014). Chronic stress impairs alpha1-adrenoceptorinduced endocannabinoid-dependent synaptic plasticity in the dorsal raphe nucleus. J Neurosci 34: 14560-14570.
91. Haller J, Bakos N, Szirmay M, Ledent C, Freund TF (2002). The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 16: 1395-1398.
92. Haller J, Barna I, Barsvari B, Gyimesi Pelczer K, Yasar S, Panlilio LV et al (2009). Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats. Psychopharmacology (Berl) 204: 607-616.
93. Haller J, Goldberg SR, Pelczer KG, Aliczki M, Panlilio LV (2013). The effects of anandamide signaling enhanced by the FAAH inhibitor URB597 on coping styles in rats. Psychopharmacology (Berl) 230: 353-362.
94. Haller J, Varga B, Ledent C, Freund TF (2004). CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav Pharmacol 15: 299-304.
95. Haring M, Marsicano G, Lutz B, Monory K (2007). Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice. Neuroscience 146: 1212-1219.
96. Hariri AR, Gorka A, Hyde LW, Kimak M, Halder I, Ducci F et al (2009). Divergent effects of genetic variation in endocannabinoid signaling on human threat- and reward-related brain function. Biol Psychiatry 66: 9-16.
97. Heinzmann JM, Thoeringer CK, Knapman A, Palme R, Holsboer F, Uhr M et al (2010). Intrahippocampal corticosterone response in mice selectively bred for extremes in stress reactivity: a microdialysis study. J Neuroendocrinol 22: 1187-1197.
98. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11: 563-583.
99. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR et al (1990). Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87: 1932-1936.
100. Hermann H, Marsicano G, Lutz B (2002). Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 109: 451-460.
101. Hermans EJ, Battaglia FP, Atsak P, de Voogd LD, Fernandez G, Roozendaal B (2014a). How the amygdala affects emotional memory by altering brain network properties. Neurobiol Learn Mem 112: 2-16.
102. Hermans EJ, Henckens MJ, Joels M, Fernandez G (2014b). Dynamic adaptation of large-scale brain networks in response to acute stressors. Trends Neurosci 37: 304-314.
103. Hermanson DJ, Gamble-George JC, Marnett LJ, Patel S (2014). Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation. Trends Pharmacol Sci 35: 358-367.
104. Hermanson DJ, Hartley ND, Gamble-George J, Brown N, Shonesy BC, Kingsley PJ et al (2013). Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation. Nat Neurosci 16: 1291-1298.
105. Hill MN, Bierer LM, Makotkine I, Golier JA, Galea S, McEwen BS et al (2013a). Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks. Psychoneuroendocrinology 38: 2952-2961.
106. Hill MN, Carrier EJ, Ho WS, Shi L, Patel S, Gorzalka BB et al (2008a). Prolonged glucocorticoid treatment decreases cannabinoid CB1 receptor density in the hippocampus. Hippocampus 18: 221-226.
107. Hill MN, Carrier EJ, McLaughlin RJ, Morrish AC, Meier SE, Hillard CJ et al (2008b). Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J Neurochem 106: 2322-2336.
108. Hill MN, Gorzalka BB (2004). Enhancement of anxiety-like responsiveness to the cannabinoid CB(1) receptor agonist HU-210 following chronic stress. Eur J Pharmacol 499: 291-295.
109. Hill MN, Gorzalka BB (2009a). The endocannabinoid system and the treatment of mood and anxiety disorders. CNS Neurol Disord Drug Targets 8: 451-458.
110. Hill MN, Hillard CJ, Bambico FR, Patel S, Gorzalka BB, Gobbi G (2009b). The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants. Trends Pharmacol Sci 30: 484-493.
111. Hill MN, Hillard CJ, McEwen BS (2011a). Alterations in corticolimbic dendritic morphology and emotional behavior in cannabinoid CB1 receptor-deficient mice parallel the effects of chronic stress. Cereb Cortex 21: 2056-2064.
112. Hill MN, Ho WS, Meier SE, Gorzalka BB, Hillard CJ (2005a). Chronic corticosterone treatment increases the endocannabinoid 2-arachidonylglycerol in the rat amygdala. Eur J Pharmacol 528: 99-102.
113. Hill MN, Kambo JS, Sun JC, Gorzalka BB, Galea LA (2006). Endocannabinoids modulate stress-induced suppression of hippocampal cell proliferation and activation of defensive behaviours. Eur J Neurosci 24: 1845-1849.
114. Hill MN, Karatsoreos IN, Hillard CJ, McEwen BS (2010a). Rapid elevations in limbic endocannabinoid content by glucocorticoid hormones in vivo. Psychoneuroendocrinology 35: 1333-1338.
115. Hill MN, Kumar SA, Filipski SB, Iverson M, Stuhr KL, Keith JM et al (2013b). Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Mol Psychiatry 18: 1125-1135.
116. Hill MN, McLaughlin RJ, Bingham B, Shrestha L, Lee TT, Gray JM et al (2010b). Endogenous cannabinoid signaling is essential for stress adaptation. Proc Natl Acad Sci USA 107: 9406-9411.
117. Hill MN, McLaughlin RJ, Morrish AC, Viau V, Floresco SB, Hillard CJ et al (2009c). Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology 34: 2733-2745.
118. Hill MN, McLaughlin RJ, Pan B, Fitzgerald ML, Roberts CJ, Lee TT et al (2011b). Recruitment of prefrontal cortical endocannabinoid signaling by glucocorticoids contributes to termination of the stress response. J Neurosci 31: 10506-10515.
119. Hill MN, Miller GE, Carrier EJ, Gorzalka BB, Hillard CJ (2009d). Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology 34: 1257-1262.
120. Hill MN, Miller GE, Ho WS, Gorzalka BB, Hillard CJ (2008c). Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 41: 48-53.
121. Hill MN, Patel S (2013c). Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses. Biol Mood Anxiety Disord 3: 19.
122. Hill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, Hillard CJ et al (2005b). Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 30: 508-515.
123. Hill MN, Tasker JG (2012). Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis. Neuroscience 204: 5-16.
124. Hillard CJ, Edgemond WS, Jarrahian A, Campbell WB (1997). Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J Neurochem 69: 631-638.
125. Hillard CJ, Weinlander KM, Stuhr KL (2012). Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience 204: 207-229.
126. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R et al (2005). An endocannabinoid mechanism for stress-induced analgesia. Nature 435: 1108-1112.
127. Hong S, Zheng G, Wu X, Snider NT, Owyang C, Wiley JW (2011). Corticosterone mediates reciprocal changes in CB 1 and TRPV1 receptors in primary sensory neurons in the chronically stressed rat. Gastroenterology 140: 627-637 e624.
128. Horder J, Browning M, Di Simplicio M, Cowen PJ, Harmer CJ (2012). Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing. J Psychopharmacol 26: 125-132.
129. Horder J, Cowen PJ, Di Simplicio M, Browning M, Harmer CJ (2009). Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers. Psychopharmacology (Berl) 205: 85-91.
130. Horder J, Harmer CJ, Cowen PJ, McCabe C (2010). Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers. Int J Neuropsychopharmacol 13: 1103-1113.
131. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161-202.
132. Hu SS, Ho YC, Chiou LC (2014). No more pain upon Gq-protein-coupled receptor activation: role of endocannabinoids. Eur J Neurosci 39: 467-484.
133. Hu W, Zhang M, Czeh B, Zhang W, Flugge G (2011). Chronic restraint stress impairs endocannabinoid mediated suppression of GABAergic signaling in the hippocampus of adult male rats. Brain Res Bull 85: 374-379.
134. Huang YC, Wang SJ, Chiou LC, Gean PW (2003). Mediation of amphetamineinduced long-term depression of synaptic transmission by CB1 cannabinoid receptors in the rat amygdala. J Neurosci 23: 10311-10320.
135. Hubner C, Bosch D, Gall A, Luthi A, Ehrlich I (2014). Ex vivo dissection of optogenetically activated mPFC and hippocampal inputs to neurons in the basolateral amygdala: implications for fear and emotional memory. Front Behav Neurosci 8: 64.
136. Janak PH, Tye KM (2015). From circuits to behaviour in the amygdala. Nature 517: 284-292.
137. Jiang W, Zhang Y, Xiao L, Van Cleemput J, Ji SP, Bai G et al (2005). Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 115: 3104-3116.
138. Joels M, Baram TZ (2009). The neuro-symphony of stress. Nat Rev Neurosci 10: 459-466.
139. Joels M, Fernandez G, Roozendaal B (2011). Stress and emotional memory: a matter of timing. Trends Cogn Sci 15: 280-288.
140. Johnson LR, Farb C, Morrison JH, McEwen BS, LeDoux JE (2005). Localization of glucocorticoid receptors at postsynaptic membranes in the lateral amygdala. Neuroscience 136: 289-299.
141. Juhasz G, Chase D, Pegg E, Downey D, Toth ZG, Stones K et al (2009). CNR1 gene is associated with high neuroticism and low agreeableness and interacts with recent negative life events to predict current depressive symptoms. Neuropsychopharmacology 34: 2019-2027.
142. Kamprath K, Romo-Parra H, Haring M, Gaburro S, Doengi M, Lutz B et al (2011). Short-term adaptation of conditioned fear responses through endocannabinoid signaling in the central amygdala. Neuropsychopharmacology 36: 652-663.
143. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009). Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89: 309-380.
144. Karatsoreos IN, McEwen BS (2011). Psychobiological allostasis: resistance, resilience and vulnerability. Trends Cogn Sci 15: 576-584.
145. Karst H, Berger S, Erdmann G, Schutz G, Joels M (2010). Metaplasticity of amygdalar responses to the stress hormone corticosterone. Proc Natl Acad Sci USA 107: 14449-14454.
146. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A et al (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9: 76-81.
147. Katona I, Freund TF (2012). Multiple functions of endocannabinoid signaling in the brain. Annu Rev Neurosci 35: 529-558.
148. Kim MJ, Loucks RA, Palmer AL, Brown AC, Solomon KM, Marchante AN et al (2011). The structural and functional connectivity of the amygdala: from normal emotion to pathological anxiety. Behav Brain Res 223: 403-410.
149. Kim SJ, Park SH, Choi SH, Moon BH, Lee KJ, Kang SW et al (2006). Effects of repeated tianeptine treatment on CRF mRNA expression in non-stressed and chronic mild stress-exposed rats. Neuropharmacology 50: 824-833.
150. Kinsey SG, O'Neal ST, Long JZ, Cravatt BF, Lichtman AH (2011). Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacol Biochem Behav 98: 21-27.
151. Kinsey SG, Wise LE, Ramesh D, Abdullah R, Selley DE, Cravatt BF et al (2013). Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects. J Pharmacol Exp Ther 345: 492-501.
152. Koob GF, Buck CL, Cohen A, Edwards S, Park PE, Schlosburg JE et al (2014). Addiction as a stress surfeit disorder. Neuropharmacology 76(Pt B): 370-382.
153. Kupferschmidt DA, Klas PG, Erb S (2012). Cannabinoid CB1 receptors mediate the effects of corticotropin-releasing factor on the reinstatement of cocaine seeking and expression of cocaine-induced behavioural sensitization. Br J Pharmacol 167: 196-206.
154. Kurrikoff K, Inno J, Matsui T, Vasar E (2008). Stress-induced analgesia in mice: evidence for interaction between endocannabinoids and cholecystokinin. Eur J Neurosci 27: 2147-2155.
155. Lee TT, Hill MN (2013). Age of stress exposure modulates the immediate and sustained effects of repeated stress on corticolimbic cannabinoid CB(1) receptor binding in male rats. Neuroscience 249: 106-114.
156. Lichtman AH, Hawkins EG, Griffin G, Cravatt BF (2002). Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J Pharmacol Exp Ther 302: 73-79.
157. Likhtik E, Paz R (2015). Amygdala-prefrontal interactions in (mal)adaptive learning. Trends Neurosci 38: 158-166.
158. Likhtik E, Pelletier JG, Paz R, Pare D (2005). Prefrontal control of the amygdala. J Neurosci 25: 7429-7437.
159. Liposits Z, Bohn MC (1993). Association of glucocorticoid receptor immunoreactivity with cell membrane and transport vesicles in hippocampal and hypothalamic neurons of the rat. J Neurosci Res 35: 14-19.
160. Lomazzo E, Bindila L, Remmers F, Lerner R, Schwitter C, Hoheisel U et al (2015). Therapeutic potential of inhibitors of endocannabinoid degradation for the treatment of stress-related hyperalgesia in an animal model of chronic pain. Neuropsychopharmacology 40: 488-501.
161. Long JZ, Nomura DK, Cravatt BF (2009). Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem Biol 16: 744-753.
162. Mailleux P, Vanderhaeghen JJ (1993). Glucocorticoid regulation of cannabinoid receptor messenger RNA levels in the rat caudate-putamen. An in situ hybridization study. Neurosci Lett 156: 51-53.
163. Makino S, Gold PW, Schulkin J (1994a). Corticosterone effects on corticotropin-releasing hormone mRNA in the central nucleus of the amygdala and the parvocellular region of the paraventricular nucleus of the hypothalamus. Brain Res 640: 105-112.
164. Makino S, Gold PW, Schulkin J (1994b). Effects of corticosterone on CRH mRNA and content in the bed nucleus of the stria terminalis; comparison with the effects in the central nucleus of the amygdala and the paraventricular nucleus of the hypothalamus. Brain Res 657: 141-149.
165. Mangieri RA, Hong KI, Piomelli D, Sinha R (2009). An endocannabinoid signal associated with desire for alcohol is suppressed in recently abstinent alcoholics. Psychopharmacology (Berl) 205: 63-72.
166. Manzanares J, Corchero J, Fuentes JA (1999). Opioid and cannabinoid receptormediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta (9)-tetrahydrocannabinol in rats. Brain Res 839: 173-179.
167. Marco EM, Scattoni ML, Rapino C, Ceci C, Chaves N, Macri S et al (2013). Emotional, endocrine and brain anandamide response to social challenge in infant male rats. Psychoneuroendocrinology 38: 2152-2162.
168. Marco EM, Viveros MP (2009). The critical role of the endocannabinoid system in emotional homeostasis: avoiding excess and deficiencies. Mini Rev Med Chem 9: 1407-1415.
169. Marrs WR, Blankman JL, Horne EA, Thomazeau A, Lin YH, Coy J et al (2010). The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci 13: 951-957.
170. Marsicano G, Kuner R (2008). Anatomical distribution of receptors, ligands and enzymes in the brain and the spinal cord: circuitries and neurochemistry. In: Kofalvi A (ed). Cannabinoids and the Brain. Springer: New York, USA, pp 161-202.
171. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG et al (2002). The endogenous cannabinoid system controls extinction of aversive memories. Nature 418: 530-534.
172. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O (2002). Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 159: 379-387.
173. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564.
174. McEwen BS (2012a). Brain on stress: how the social environment gets under the skin. Proc Natl Acad Sci USA 109(Suppl 2): 17180-17185.
175. McEwen BS (2012b). The ever-changing brain: cellular and molecular mechanisms for the effects of stressful experiences. Dev Neurobiol 72: 878-890.
176. McGaugh JL (2015). Consolidating memories. Annu Rev Psychol 66: 1-24.
177. McIntyre CK, Hatfield T, McGaugh JL (2002). Amygdala norepinephrine levels after training predict inhibitory avoidance retention performance in rats. Eur J Neurosci 16: 1223-1226.
178. McLaughlin RJ, Hill MN, Bambico FR, Stuhr KL, Gobbi G, Hillard CJ et al (2012). Prefrontal cortical anandamide signaling coordinates coping responses to stress through a serotonergic pathway. Eur Neuropsychopharmacol 22: 664-671.
179. McLaughlin RJ, Hill MN, Dang SS, Wainwright SR, Galea LA, Hillard CJ et al (2013). Upregulation of CB(1) receptor binding in the ventromedial prefrontal cortex promotes proactive stress-coping strategies following chronic stress exposure. Behav Brain Res 237: 333-337.
180. McPartland JM, Glass M, Pertwee RG (2007). Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br J Pharmacol 152: 583-593.
181. Mechoulam R, Parker LA (2013). The endocannabinoid system and the brain. Annu Rev Psychol 64: 21-47.
182. Merlo Pich E, Lorang M, Yeganeh M, Rodriguez de Fonseca F, Raber J, Koob GF et al (1995). Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci 15: 5439-5447.
183. Mikics E, Vas J, Aliczki M, Halasz J, Haller J (2009). Interactions between the anxiogenic effects of CB1 gene disruption and 5-HT3 neurotransmission. Behav Pharmacol 20: 265-272.
184. Mitchell PB, Morris MJ (2007). Depression and anxiety with rimonabant. Lancet 370: 1671-1672.
185. Morena M, Campolongo P (2014a). The endocannabinoid system: An emotional buffer in the modulation of memory function. Neurobiol Learn Mem 112C: 30-43.
186. Morena M, Roozendaal B, Trezza V, Ratano P, Peloso A, Hauer D et al (2014b). Endogenous cannabinoid release within prefrontal-limbic pathways affects memory consolidation of emotional training. Proc Natl Acad Sci USA 111: 18333-18338.
187. Morozov YM, Torii M, Rakic P (2009). Origin, early commitment, migratory routes, and destination of cannabinoid type 1 receptor-containing interneurons. Cereb Cortex 19(Suppl 1): i78-i89.
188. Naidu PS, Varvel SA, Ahn K, Cravatt BF, Martin BR, Lichtman AH (2007). Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl) 192: 61-70.
189. Navarria A, Tamburella A, Iannotti FA, Micale V, Camillieri G, Gozzo L et al (2014). The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis. Pharmacol Res 87: 151-159.
190. Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A et al (2013). Elevated brain cannabinoid CB receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry 18: 1034-1040.
191. Neumeister A, Seidel J, Ragen BJ, Pietrzak RH (2015). Translational evidence for a role of endocannabinoids in the etiology and treatment of posttraumatic stress disorder. Psychoneuroendocrinology 51: 577-584.
192. Newsom RJ, Osterlund C, Masini CV, Day HE, Spencer RL, Campeau S (2012). Cannabinoid receptor type 1 antagonism significantly modulates basal and loud noise induced neural and hypothalamic-pituitary-adrenal axis responses in male Sprague-Dawley rats. Neuroscience 204: 64-73.
193. Ohno-Shosaku T, Kano M (2014). Endocannabinoid-mediated retrograde modulation of synaptic transmission. Curr Opin Neurobiol 29: 1-8.
194. Oitzl MS, de Kloet ER (1992). Selective corticosteroid antagonists modulate specific aspects of spatial orientation learning. Behav Neurosci 106: 62-71.
195. Olango WM, Roche M, Ford GK, Harhen B, Finn DP (2012). The endocannabinoid system in the rat dorsolateral periaqueductal grey mediates fear-conditioned analgesia and controls fear expression in the presence of nociceptive tone. Br J Pharmacol 165: 2549-2560.
196. Oropeza VC, Mackie K, Van Bockstaele EJ (2007). Cannabinoid receptors are localized to noradrenergic axon terminals in the rat frontal cortex. Brain Res 1127: 36-44.
197. Pamplona FA, Bitencourt RM, Takahashi RN (2008). Short- and long-term effects of cannabinoids on the extinction of contextual fear memory in rats. Neurobiol Learn Mem 90: 290-293.
198. Patel S, Cravatt BF, Hillard CJ (2005a). Synergistic interactions between cannabinoids and environmental stress in the activation of the central amygdala. Neuropsychopharmacology 30: 497-507.
199. Patel S, Hillard CJ (2008). Adaptations in endocannabinoid signaling in response to repeated homotypic stress: a novel mechanism for stress habituation. Eur J Neurosci 27: 2821-2829.
200. Patel S, Kingsley PJ, Mackie K, Marnett LJ, Winder DG (2009). Repeated homotypic stress elevates 2-arachidonoylglycerol levels and enhances short-term endocannabinoid signaling at inhibitory synapses in basolateral amygdala. Neuropsychopharmacology 34: 2699-2709.
201. Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ (2004). Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 145: 5431-5438.
202. Patel S, Roelke CT, Rademacher DJ, Hillard CJ (2005b). Inhibition of restraint stressinduced neural and behavioural activation by endogenous cannabinoid signalling. Eur J Neurosci 21: 1057-1069.
203. Pecoraro N, Dallman MF, Warne JP, Ginsberg AB, Laugero KD, la Fleur SE et al (2006). From Malthus to motive: how the HPA axis engineers the phenotype, yoking needs to wants. Prog Neurobiol 79: 247-340.
204. Pertwee RG (2005). Pharmacological actions of cannabinoids. Handb Exp Pharmacol 168: 1-51.
205. Pittenger C, Duman RS (2008). Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 33: 88-109.
206. Popoli M, Yan Z, McEwen BS, Sanacora G (2011). The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci 13: 22-37.
207. Pruessner JC, Dedovic K, Pruessner M, Lord C, Buss C, Collins L et al (2010). Stress regulation in the central nervous system: evidence from structural and functional neuroimaging studies in human populations-2008 Curt Richter Award Winner. Psychoneuroendocrinology 35: 179-191.
208. Qin Z, Zhou X, Pandey NR, Vecchiarelli HA, Stewart CA, Zhang X et al (2015). Chronic stress induces anxiety via an amygdalar intracellular cascade that impairs endocannabinoid signaling. Neuron 85: 1319-1331.
209. Quirarte GL, Roozendaal B, McGaugh JL (1997). Glucocorticoid enhancement of memory storage involves noradrenergic activation in the basolateral amygdala. Proc Natl Acad Sci USA 94: 14048-14053.
210. Racz I, Bilkei-Gorzo A, Toth ZE, Michel K, Palkovits M, Zimmer A (2003). A critical role for the cannabinoid CB1 receptors in alcohol dependence and stressstimulated ethanol drinking. J Neurosci 23: 2453-2458.
211. Rademacher DJ, Hillard CJ (2007). Interactions between endocannabinoids and stress-induced decreased sensitivity to natural reward. Prog Neuropsychopharmacol Biol Psychiatry 31: 633-641.
212. Rademacher DJ, Meier SE, Shi L, Ho WS, Jarrahian A, Hillard CJ (2008). Effects of acute and repeated restraint stress on endocannabinoid content in the amygdala, ventral striatum, and medial prefrontal cortex in mice. Neuropharmacology 54: 108-116.
213. Radley JJ (2012). Toward a limbic cortical inhibitory network: implications for hypothalamic-pituitary-adrenal responses following chronic stress. Front Behav Neurosci 6: 7.
214. Ramikie TS, Nyilas R, Bluett RJ, Gamble-George JC, Hartley ND, Mackie K et al (2014). Multiple mechanistically distinct modes of endocannabinoid mobilization at central amygdala glutamatergic synapses. Neuron 81: 1111-1125.
215. Ramikie TS, Patel S (2012). Endocannabinoid signaling in the amygdala: anatomy, synaptic signaling, behavior, and adaptations to stress. Neuroscience 204: 38-52.
216. Refojo D, Echenique C, Muller MB, Reul JM, Deussing JM, Wurst W et al (2005). Corticotropin-releasing hormone activates ERK1/2 MAPK in specific brain areas. Proc Natl Acad Sci USA 102: 6183-6188.
217. Reich CG, Mihalik GR, Iskander AN, Seckler JC, Weiss MS (2013). Adolescent chronic mild stress alters hippocampal CB1 receptor-mediated excitatory neurotransmission and plasticity. Neuroscience 253: 444-454.
218. Reich CG, Taylor ME, McCarthy MM (2009). Differential effects of chronic unpredictable stress on hippocampal CB1 receptors in male and female rats. Behav Brain Res 203: 264-269.
219. Rey AA, Purrio M, Viveros MP, Lutz B (2012). Biphasic effects of cannabinoids in anxiety responses: CB1 and GABA(B) receptors in the balance of GABAergic and glutamatergic neurotransmission. Neuropsychopharmacology 37: 2624-2634.
220. Roberto M, Cruz M, Bajo M, Siggins GR, Parsons LH, Schweitzer P (2010). The endocannabinoid system tonically regulates inhibitory transmission and depresses the effect of ethanol in central amygdala. Neuropsychopharmacology 35: 1962-1972.
221. Roberts CJ, Stuhr KL, Hillard CJ (2012). Swim stress differentially affects limbic contents of 2-arachidonoylglycerol and 2-oleoylglycerol. Neuroscience 204: 74-82.
222. Roberts CJ, Stuhr KL, Hutz MJ, Raff H, Hillard CJ (2014). Endocannabinoid signaling in hypothalamic-pituitary-adrenocortical axis recovery following stress: effects of indirect agonists and comparison of male and female mice. Pharmacol Biochem Behav 117: 17-24.
223. Rodrigues SM, LeDoux JE, Sapolsky RM (2009). The influence of stress hormones on fear circuitry. Annu Rev Neurosci 32: 289-313.
224. Roozendaal B (2000). 1999 Curt P. Richter award. Glucocorticoids and the regulation of memory consolidation. Psychoneuroendocrinology 25: 213-238.
225. Roozendaal B, Brunson KL, Holloway BL, McGaugh JL, Baram TZ (2002). Involvement of stress-released corticotropin-releasing hormone in the basolateral amygdala in regulating memory consolidation. Proc Natl Acad Sci USA 99: 13908-13913.
226. Roozendaal B, McEwen BS, Chattarji S (2009). Stress, memory and the amygdala. Nat Rev Neurosci 10: 423-433.
227. Roozendaal B, McGaugh JL (1996). Amygdaloid nuclei lesions differentially affect glucocorticoid-induced memory enhancement in an inhibitory avoidance task. Neurobiol Learn Mem 65: 1-8.
228. Roozendaal B, McGaugh JL (1997). Glucocorticoid receptor agonist and antagonist administration into the basolateral but not central amygdala modulates memory storage. Neurobiol Learn Mem 67: 176-179.
229. Rossi S, De Chiara V, Musella A, Kusayanagi H, Mataluni G, Bernardi G et al (2008). Chronic psychoemotional stress impairs cannabinoid-receptor-mediated control of GABA transmission in the striatum. J Neurosci 28: 7284-7292.
230. Rossi S, De Chiara V, Musella A, Sacchetti L, Cantarella C, Castelli M et al (2010). Preservation of striatal cannabinoid CB1 receptor function correlates with the antianxiety effects of fatty acid amide hydrolase inhibition. Mol Pharmacol 78: 260-268.
231. Rubino T, Realini N, Castiglioni C, Guidali C, Vigano D, Marras E et al (2008). Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb Cortex 18: 1292-1301.
232. Ruehle S, Remmers F, Romo-Parra H, Massa F, Wickert M, Wortge S et al (2013). Cannabinoid CB1 receptor in dorsal telencephalic glutamatergic neurons: distinctive sufficiency for hippocampus-dependent and amygdala-dependent synaptic and behavioral functions. J Neurosci 33: 10264-10277.
233. Salehi B, Cordero MI, Sandi C (2010). Learning under stress: the inverted-U-shape function revisited. Learn Mem 17: 522-530.
234. Sanchis-Segura C, Cline BH, Marsicano G, Lutz B, Spanagel R (2004). Reduced sensitivity to reward in CB1 knockout mice. Psychopharmacology (Berl) 176: 223-232.
235. Sandi C, Cordero MI, Ugolini A, Varea E, Caberlotto L, Large CH (2008). Chronic stress-induced alterations in amygdala responsiveness and behavior-modulation by trait anxiety and corticotropin-releasing factor systems. Eur J Neurosci 28: 1836-1848.
236. Sandi C, Rose SP (1994). Corticosterone enhances long-term retention in one-dayold chicks trained in a weak passive avoidance learning paradigm. Brain Res 647: 106-112.
237. Santucci V, Storme JJ, Soubrie P, Le Fur G (1996). Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sci 58: PL103-PL110.
238. Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG et al (2010). Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 13: 1113-1119.
239. Sciolino NR, Zhou W, Hohmann AG (2011). Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. Pharmacol Res 64: 226-234.
240. Senst L, Bains J (2014). Neuromodulators, stress and plasticity: a role for endocannabinoid signalling. J Exp Biol 217: 102-108.
241. Shonesy BC, Bluett RJ, Ramikie TS, Baldi R, Hermanson DJ, Kingsley PJ et al (2014). Genetic disruption of 2-arachidonoylglycerol synthesis reveals a key role for endocannabinoid signaling in anxiety modulation. Cell Rep 9: 1644-1653.
242. Singh ME, Verty AN, Price I, McGregor IS, Mallet PE (2004). Modulation of morphineinduced Fos-immunoreactivity by the cannabinoid receptor antagonist SR 141716. Neuropharmacology 47: 1157-1169.
243. Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF (2002). A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci USA 99: 8394-8399.
244. Sipe JC, Scott TM, Murray S, Harismendy O, Simon GM, Cravatt BF et al (2010). Biomarkers of endocannabinoid system activation in severe obesity. PLoS One 5: e8792.
245. Sparta DR, Jennings JH, Ung RL, Stuber GD (2013). Optogenetic strategies to investigate neural circuitry engaged by stress. Behav Brain Res 255: 19-25.
246. Steiner MA, Marsicano G, Nestler EJ, Holsboer F, Lutz B, Wotjak CT (2008). Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. Psychoneuroendocrinology 33: 54-67.
247. Steiner MA, Wotjak CT (2008). Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis. Prog Brain Res 170: 397-432.
248. Sterrenburg L, Gaszner B, Boerrigter J, Santbergen L, Bramini M, Elliott E et al (2011). Chronic stress induces sex-specific alterations in methylation and expression of corticotropin-releasing factor gene in the rat. PLoS One 6: e28128.
249. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K et al (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215: 89-97.
250. Sumislawski JJ, Ramikie TS, Patel S (2011). Reversible gating of endocannabinoid plasticity in the amygdala by chronic stress: a potential role for monoacylglycerol lipase inhibition in the prevention of stress-induced behavioral adaptation. Neuropsychopharmacology 36: 2750-2761.
251. Suzuki A, Josselyn SA, Frankland PW, Masushige S, Silva AJ, Kida S (2004). Memory reconsolidation and extinction have distinct temporal and biochemical signatures. J Neurosci 24: 4787-4795.
252. Swanson LW, Simmons DM (1989). Differential steroid hormone and neural influences on peptide mRNA levels in CRH cells of the paraventricular nucleus: a hybridization histochemical study in the rat. J Comp Neurol 285: 413-435.
253. Swartz JR, Knodt AR, Radtke SR, Hariri AR (2015). A neural biomarker of psychological vulnerability to future life stress. Neuron 85: 505-511.
254. Tallett AJ, Blundell JE, Rodgers RJ (2007). Grooming, scratching and feeding: role of response competition in acute anorectic response to rimonabant in male rats. Psychopharmacology (Berl) 195: 27-39.
255. Tan H, Lauzon NM, Bishop SF, Chi N, Bechard M, Laviolette SR (2011). Cannabinoid transmission in the basolateral amygdala modulates fear memory formation via functional inputs to the prelimbic cortex. J Neurosci 31: 5300-5312.
256. Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD et al (2010). Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 376: 517-523.
257. Ulrich-Lai YM, Herman JP (2009). Neural regulation of endocrine and autonomic stress responses. Nat Rev Neurosci 10: 397-409.
258. Uriguen L, Perez-Rial S, Ledent C, Palomo T, Manzanares J (2004). Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 46: 966-973.
259. Valverde O, Ledent C, Beslot F, Parmentier M, Roques BP (2000). Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors. Eur J Neurosci 12: 533-539.
260. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K et al (2005). Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310: 329-332.
261. Varvel SA, Lichtman AH (2002). Evaluation of CB1 receptor knockout mice in the Morris water maze. J Pharmacol Exp Ther 301: 915-924.
262. Vaughn LK, Mantsch JR, Vranjkovic O, Stroh G, Lacourt M, Kreutter M et al (2012). Cannabinoid receptor involvement in stress-induced cocaine reinstatement: potential interaction with noradrenergic pathways. Neuroscience 204: 117-124.
263. Veinante P, Yalcin I, Barrot M (2013). The amygdala between sensation and affect: a role in pain. J Mol Psychiatry 1: 9.
264. Wade MR, Degroot A, Nomikos GG (2006). Cannabinoid CB1 receptor antagonism modulates plasma corticosterone in rodents. Eur J Pharmacol 551: 162-167.
265. Wamsteeker Cusulin JI, Senst L, Teskey GC, Bains JS (2014). Experience salience gates endocannabinoid signaling at hypothalamic synapses. J Neurosci 34: 6177-6181.
266. Wamsteeker JI, Kuzmiski JB, Bains JS (2010). Repeated stress impairs endocannabinoid signaling in the paraventricular nucleus of the hypothalamus. J Neurosci 30: 11188-11196.
267. Wang J, Shen RY, Haj-Dahmane S (2012a). Endocannabinoids mediate the glucocorticoid-induced inhibition of excitatory synaptic transmission to dorsal raphe serotonin neurons. J Physiol 590: 5795-5808.
268. Wang M, Hill MN, Zhang L, Gorzalka BB, Hillard CJ, Alger BE (2012b). Acute restraint stress enhances hippocampal endocannabinoid function via glucocorticoid receptor activation. J Psychopharmacol 26: 56-70.
269. Wang W, Sun D, Pan B, Roberts CJ, Sun X, Hillard CJ et al (2010). Deficiency in endocannabinoid signaling in the nucleus accumbens induced by chronic unpredictable stress. Neuropsychopharmacology 35: 2249-2261.
270. Wittmann G, Deli L, Kallo I, Hrabovszky E, Watanabe M, Liposits Z et al (2007). Distribution of type 1 cannabinoid receptor (CB1)-immunoreactive axons in the mouse hypothalamus. J Comp Neurol 503: 270-279.
271. Wolkers CP, Barbosa Junior A, Menescal-de-Oliveira L, Hoffmann A (2015). Acute administration of a cannabinoid CB1 receptor antagonist impairs stress-induced antinociception in fish. Physiol Behav 142: 37-41.
272. Yoshida T, Uchigashima M, Yamasaki M, Katona I, Yamazaki M, Sakimura K et al (2011). Unique inhibitory synapse with particularly rich endocannabinoid signaling machinery on pyramidal neurons in basal amygdaloid nucleus. Proc Natl Acad Sci USA 108: 3059-3064.
273. Zhang Z, Wang W, Zhong P, Liu SJ, Long JZ, Zhao L et al (2015). Blockade of 2-arachidonoylglycerol hydrolysis produces antidepressant-like effects and enhances adult hippocampal neurogenesis and synaptic plasticity. Hippocampus 25: 16-26.
274. Zhong P, Wang W, Pan B, Liu X, Zhang Z, Long JZ et al (2014). Monoacylglycerol lipase inhibition blocks chronic stress-induced depressive-like behaviors via activation of mTOR signaling. Neuropsychopharmacology 39: 1763-1776.
275. Zoppi S, Perez Nievas BG, Madrigal JL, Manzanares J, Leza JC, Garcia-Bueno B (2011). Regulatory role of cannabinoid receptor 1 in stress-induced excitotoxicity and neuroinflammation. Neuropsychopharmacology 36: 805-818.